Common changes in cerebral blood flow in patients with social phobia treated with citalopram or cognitive-behavioral therapy - PubMed (original) (raw)
Clinical Trial
Common changes in cerebral blood flow in patients with social phobia treated with citalopram or cognitive-behavioral therapy
Tomas Furmark et al. Arch Gen Psychiatry. 2002 May.
Abstract
Background: Neurofunctional changes underlying effective antianxiety treatments are incompletely characterized. This study explored the effects of citalopram and cognitive-behavioral therapy on regional cerebral blood flow (rCBF) in social phobia.
Methods: By means of positron emission tomography with oxygen 15-labeled water, rCBF was assessed in 18 previously untreated patients with social phobia during an anxiogenic public speaking task. Patients were matched for sex, age, and phobia severity, based on social anxiety questionnaire data, and randomized to citalopram medication, cognitive-behavioral group therapy, or a waiting-list control group. Scans were repeated after 9 weeks of treatment or waiting time. Outcome was assessed by subjective and psychophysiological state anxiety measures and self-report questionnaires. Questions were readministered after 1 year.
Results: Symptoms improved significantly and roughly equally with citalopram and cognitive-behavioral therapy, whereas the waiting-list group remained unchanged. Four patients in each treated group and 1 waiting-list patient were classified as responders. Within both treated groups, and in responders regardless of treatment approach, improvement was accompanied by a decreased rCBF-response to public speaking bilaterally in the amygdala, hippocampus, and the periamygdaloid, rhinal, and parahippocampal cortices. Between-group comparisons confirmed that rCBF in these regions decreased significantly more in treated groups than control subjects, and in responders than nonresponders, particularly in the right hemisphere. The degree of amygdalar-limbic attenuation was associated with clinical improvement a year later.
Conclusions: Common sites of action for citalopram and cognitive-behavioral treatment of social anxiety were observed in the amygdala, hippocampus, and neighboring cortical areas, ie, brain regions subserving bodily defense reactions to threat.
Similar articles
- Cerebral blood flow changes after treatment of social phobia with the neurokinin-1 antagonist GR205171, citalopram, or placebo.
Furmark T, Appel L, Michelgård A, Wahlstedt K, Ahs F, Zancan S, Jacobsson E, Flyckt K, Grohp M, Bergström M, Pich EM, Nilsson LG, Bani M, Långström B, Fredrikson M. Furmark T, et al. Biol Psychiatry. 2005 Jul 15;58(2):132-42. doi: 10.1016/j.biopsych.2005.03.029. Biol Psychiatry. 2005. PMID: 16038684 Clinical Trial. - Single photon emission computed tomography (SPECT) of anxiety disorders before and after treatment with citalopram.
Carey PD, Warwick J, Niehaus DJ, van der Linden G, van Heerden BB, Harvey BH, Seedat S, Stein DJ. Carey PD, et al. BMC Psychiatry. 2004 Oct 14;4:30. doi: 10.1186/1471-244X-4-30. BMC Psychiatry. 2004. PMID: 15482603 Free PMC article. - Disentangling the web of fear: amygdala reactivity and functional connectivity in spider and snake phobia.
Ahs F, Pissiota A, Michelgård A, Frans O, Furmark T, Appel L, Fredrikson M. Ahs F, et al. Psychiatry Res. 2009 May 15;172(2):103-8. doi: 10.1016/j.pscychresns.2008.11.004. Epub 2009 Mar 24. Psychiatry Res. 2009. PMID: 19321315 - [Neurobiology and pharmacotherapy of social phobia].
Aouizerate B, Martin-Guehl C, Tignol J. Aouizerate B, et al. Encephale. 2004 Jul-Aug;30(4):301-13. doi: 10.1016/s0013-7006(04)95442-5. Encephale. 2004. PMID: 15538306 Review. French. - Cerebral blood flow during anxiety provocation.
Fredrikson M, Fischer H, Wik G. Fredrikson M, et al. J Clin Psychiatry. 1997;58 Suppl 16:16-21. J Clin Psychiatry. 1997. PMID: 9430505 Review.
Cited by
- Individual cognitive therapy reduces frontal-thalamic resting-state functional connectivity in social anxiety disorder.
Kurita K, Obata T, Sutoh C, Matsuzawa D, Yoshinaga N, Kershaw J, Chhatkuli RB, Ota J, Shimizu E, Hirano Y. Kurita K, et al. Front Psychiatry. 2023 Dec 21;14:1233564. doi: 10.3389/fpsyt.2023.1233564. eCollection 2023. Front Psychiatry. 2023. PMID: 38179253 Free PMC article. - The cerebellum and anxiety.
Chin PW, Augustine GJ. Chin PW, et al. Front Cell Neurosci. 2023 Feb 22;17:1130505. doi: 10.3389/fncel.2023.1130505. eCollection 2023. Front Cell Neurosci. 2023. PMID: 36909285 Free PMC article. - Systematic literature review of human studies assessing the efficacy of cannabidiol for social anxiety.
Fliegel DK, Lichenstein SD. Fliegel DK, et al. Psychiatry Res Commun. 2022 Dec;2(4):100074. doi: 10.1016/j.psycom.2022.100074. Epub 2022 Sep 13. Psychiatry Res Commun. 2022. PMID: 36875967 Free PMC article. - Cognitive Behavioral Therapy for Anxiety in Parkinson's Disease Induces Functional Brain Changes.
Carey G, Lopes R, Moonen AJH, Mulders AEP, de Jong JJA, Kuchcinski G, Defebvre L, Kuijf ML, Dujardin K, Leentjens AFG. Carey G, et al. J Parkinsons Dis. 2023;13(1):93-103. doi: 10.3233/JPD-223527. J Parkinsons Dis. 2023. PMID: 36591659 Free PMC article. Clinical Trial. - Serotonin and dopamine transporter availability in social anxiety disorder after combined treatment with escitalopram and cognitive-behavioral therapy.
Hjorth O, Frick A, Gingnell M, Engman J, Björkstrand J, Faria V, Alaie I, Carlbring P, Andersson G, Jonasson M, Lubberink M, Antoni G, Reis M, Wahlstedt K, Fredrikson M, Furmark T. Hjorth O, et al. Transl Psychiatry. 2022 Oct 7;12(1):436. doi: 10.1038/s41398-022-02187-3. Transl Psychiatry. 2022. PMID: 36202797 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical